Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 355

1.

Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines.

Aliabadi N, Tate JE, Parashar UD.

Clin Microbiol Infect. 2016 Apr 26. pii: S1198-743X(16)30022-2. doi: 10.1016/j.cmi.2016.03.007. [Epub ahead of print]

PMID:
27129416
2.

Age at First Rotavirus Vaccination and Risk of Intussusception in Infants: A Public Health Modeling Analysis.

Yung CF, Chong CY, Thoon KC.

Drug Saf. 2016 Apr 11. [Epub ahead of print]

PMID:
27067440
3.

Evaluation of the Intussusception Risk after Pentavalent Rotavirus Vaccination in Finnish Infants.

Leino T, Ollgren J, Strömberg N, Elonsalo U.

PLoS One. 2016 Mar 7;11(3):e0144812. doi: 10.1371/journal.pone.0144812. eCollection 2016.

4.

Hospital-based surveillance of intussusception among infants.

Fernandes EG, Leshem E, Patel M, Flannery B, Pellini AC, Veras MA, Sato HK.

J Pediatr (Rio J). 2016 Mar-Apr;92(2):181-7. doi: 10.1016/j.jped.2015.06.008. Epub 2016 Jan 21.

5.

Post-Marketing Benefit-Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis.

Ledent E, Lieftucht A, Buyse H, Sugiyama K, Mckenna M, Holl K.

Drug Saf. 2016 Mar;39(3):219-30. doi: 10.1007/s40264-015-0376-7.

6.

[Anti-rotavirus and intussusception: no evidence to discontinue the universal vaccination policy].

Bonanni P, Signorelli C.

Ig Sanita Pubbl. 2015 Sep-Oct;71(5):549-57. Italian.

PMID:
26722831
7.

Value of Post-Licensure Data on Benefits and Risks of Vaccination to Inform Vaccine Policy: The Example of Rotavirus Vaccines.

Parashar UD, Cortese MM, Payne DC, Lopman B, Yen C, Tate JE.

Am J Prev Med. 2015 Dec;49(6 Suppl 4):S377-82. doi: 10.1016/j.amepre.2015.09.005. Review.

PMID:
26590437
8.

Quantifying the impact of time-varying baseline risk adjustment in the self-controlled risk interval design.

Li L, Kulldorff M, Russek-Cohen E, Kawai AT, Hua W.

Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1304-12. doi: 10.1002/pds.3885. Epub 2015 Oct 13.

PMID:
26464236
9.

The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials.

Black S.

Expert Rev Vaccines. 2015;14(12):1543-8. doi: 10.1586/14760584.2015.1091733. Epub 2015 Sep 28.

PMID:
26414015
10.

Intussusception Cases Among Children Admitted to Referral Hospitals in Kenya, 2002-2013: Implications for Monitoring Postlicensure Safety of Rotavirus Vaccines in Africa.

Omore R, Osawa F, Musia J, Rha B, Ismail A, Kiulia NM, Moke F, Vulule J, Wainaina AM, Tole J, Machoki SM, Nuorti JP, Breiman RF, Parashar UD, Montgomery JM, Tate JE.

J Pediatric Infect Dis Soc. 2015 Aug 25. pii: piv051. [Epub ahead of print]

PMID:
26407281
11.

Intussusception after monovalent rotavirus vaccine-United States, Vaccine Adverse Event Reporting System (VAERS), 2008-2014.

Haber P, Parashar UD, Haber M, DeStefano F.

Vaccine. 2015 Sep 11;33(38):4873-7. doi: 10.1016/j.vaccine.2015.07.054. Epub 2015 Aug 11.

PMID:
26276687
12.

Analysis of hospitalizations due to intussusception in Sicily in the pre-rotavirus vaccination era (2003-2012).

Costantino C, Restivo V, Cuccia M, Furnari R, Amodio E, Vitale F.

Ital J Pediatr. 2015 Aug 1;41:52. doi: 10.1186/s13052-015-0160-4.

13.

Value of post-licensure data on benefits and risks of vaccination to inform vaccine policy: The example of rotavirus vaccines.

Parashar UD, Cortese MM, Payne DC, Lopman B, Yen C, Tate JE.

Vaccine. 2015 Nov 27;33 Suppl 4:D55-9. doi: 10.1016/j.vaccine.2015.05.094. Epub 2015 Jun 27. Review.

PMID:
26122581
14.

National Vaccine Injury Compensation Program: Addition of Intussusception as Injury for Rotavirus Vaccines to the Vaccine Injury Table. Final rule.

Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

Fed Regist. 2015 Jun 23;80(120):35848-51.

15.

Intussusception following rotavirus vaccination in the Valencia Region, Spain.

Pérez-Vilar S, Díez-Domingo J, Puig-Barberà J, Gil-Prieto R, Romio S.

Hum Vaccin Immunother. 2015;11(7):1848-52. doi: 10.1080/21645515.2015.1049787.

16.

Risk of Intussusception After Rotavirus Vaccination: Meta-analysis of Postlicensure Studies.

Rosillon D, Buyse H, Friedland LR, Ng SP, Velázquez FR, Breuer T.

Pediatr Infect Dis J. 2015 Jul;34(7):763-8. doi: 10.1097/INF.0000000000000715.

PMID:
26069948
17.

Trends in Hospitalizations for Intussusception in California in Relationship to the Introduction of New Rotavirus Vaccines, 1985-2010.

Contopoulos-Ioannidis DG, Halpern MS, Maldonado Y.

Pediatr Infect Dis J. 2015 Jul;34(7):712-7. doi: 10.1097/INF.0000000000000653.

PMID:
26069946
18.

Indian rotavirus vaccine concern over intussusception is unfounded, say researchers.

Pulla P.

BMJ. 2015 May 27;350:h2867. doi: 10.1136/bmj.h2867. No abstract available.

PMID:
26016673
19.

Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.

Lappalainen S, Pastor AR, Malm M, López-Guerrero V, Esquivel-Guadarrama F, Palomares LA, Vesikari T, Blazevic V.

Arch Virol. 2015 Aug;160(8):2075-8. doi: 10.1007/s00705-015-2461-8. Epub 2015 May 29.

20.

Post-marketing monitoring of intussusception after rotavirus vaccination in Japan.

Bauchau V, Van Holle L, Mahaux O, Holl K, Sugiyama K, Buyse H.

Pharmacoepidemiol Drug Saf. 2015 Jul;24(7):765-70. doi: 10.1002/pds.3800. Epub 2015 May 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk